MILWAUKEE, May 4, 2020 /PRNewswire/ -- Ademi & O'Reilly,
LLP is investigating Stemline (Nasdaq: STML) for possible
breaches of fiduciary duty and other violations of the law in
connection with the sale to Menarini.
Click here to learn how to join the action:
http://ademilaw.com/case/stemline-therapeutics-inc or call
Guri Ademi toll-free at
866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Stemline's financial outlook
is improving and yet shareholders will receive only $12.50 per share, consisting of an upfront
payment of $11.50 in cash and one
non-tradeable Contingent Value Right that will entitle each holder
to an additional $1.00 in cash per
share upon completion of the first sale of ELZONRIS in any EU5
country after European Commission approval representing an
enterprise value of approximately $677
million. The merger agreement unreasonably limits
competing bids for Stemline by prohibiting solicitation of
further bids, and imposing a termination penalty if
Stemline accepts a superior bid. Stemline insiders will
receive millions of dollars as part of change of control
arrangements. We are investigating the conduct of Stemline's board
of directors, and whether they are (i) fulfilling their fiduciary
duties to all shareholders, and (ii) obtaining a fair and
reasonable price for Stemline.
If you own common stock in Stemline and wish to obtain
additional information, please contact Guri
Ademi either at gademi@ademilaw.com or toll-free:
866-264-3995, or
http://ademilaw.com/case/stemline-therapeutics-inc.
We specialize in shareholder litigation involving buyouts,
mergers, and individual shareholder rights throughout the country.
For more information, please feel free to call us. Attorney
advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-stemline-therapeutics-inc-has-obtained-a-fair-price-in-its-sale-to-menarini-group-301051920.html
SOURCE Ademi & O'Reilly, LLP